Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V.

Psychopharmacology (Berl). 2006 Jan;184(2):254-6. Epub 2005 Dec 22.

PMID:
16374600
2.

Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.

Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG.

J Clin Psychiatry. 2017 Jul;78(7):e766-e773. doi: 10.4088/JCP.16m11101.

PMID:
28617566
3.

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.

Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S.

J Clin Pharm Ther. 2016 Apr;41(2):214-9. doi: 10.1111/jcpt.12370. Epub 2016 Mar 2.

PMID:
26931055
4.

Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.

Tzavellas E, Karaiskos D, Ilias I, Liappas I, Paparrigopoulos T.

Psychiatriki. 2014 Jul-Sep;25(3):179-84.

PMID:
25367661
5.

Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder.

Oulis P, Masdrakis VG, Karapoulios E, Karakatsanis NA, Kouzoupis AV, Konstantakopoulos G, Soldatos CR.

World J Biol Psychiatry. 2009;10(4 Pt 3):953-5. doi: 10.1080/15622970701739526.

PMID:
19224410
6.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.

Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.

PMID:
16585942
7.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
8.

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

Bogetto F, Bellino S, Vaschetto P, Ziero S.

Psychiatry Res. 2000 Oct 30;96(2):91-8.

PMID:
11063782
9.

Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.

Saxena S, Wang D, Bystritsky A, Baxter LR Jr.

J Clin Psychiatry. 1996 Jul;57(7):303-6.

PMID:
8666572
10.

Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.

Seedat S, Stein DJ.

Int Clin Psychopharmacol. 1999 Nov;14(6):353-6. Erratum in: Int Clin Psychopharmacol 2000 Jul;15(4):244.

PMID:
10565802
11.

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Aboujaoude E, Barry JJ, Gamel N.

J Clin Psychopharmacol. 2009 Feb;29(1):51-5. doi: 10.1097/JCP.0b013e318192e9a4.

PMID:
19142108
12.

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.

Sarris J, Oliver G, Camfield DA, Dean OM, Dowling N, Smith DJ, Murphy J, Menon R, Berk M, Blair-West S, Ng CH.

CNS Drugs. 2015 Sep;29(9):801-9. doi: 10.1007/s40263-015-0272-9.

PMID:
26374743
13.

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.

Ak M, Bulut SD, Bozkurt A, Ozsahin A.

Adv Ther. 2011 Apr;28(4):341-8. doi: 10.1007/s12325-011-0011-7. Epub 2011 Mar 21.

PMID:
21437763
14.

The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.

McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH.

J Clin Psychopharmacol. 1993 Oct;13(5):354-8.

PMID:
8227493
15.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
16.
17.

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

Weiss EL, Potenza MN, McDougle CJ, Epperson CN.

J Clin Psychiatry. 1999 Aug;60(8):524-7.

PMID:
10485634
18.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
19.

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Ringold AL, Elliott MA.

J Clin Psychiatry. 2000 Jul;61(7):514-7.

PMID:
10937610
20.

Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.

McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH.

J Clin Psychiatry. 1995 Nov;56(11):526-8.

PMID:
7592506

Supplemental Content

Support Center